Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) U.S. — Reported Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2025
0.8%
Period ended Dec 31, 2025
Change on a year earlier
-5.1 pts
5.9% in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) U.S. — Reported Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.8% | -5.1 pts | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 5.9% | -11.3 pts | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 17.2% | +16.9 pts | SEC Filing (0001628280-24-002009) ↗ |
| FY2022 | Dec 31, 2022 | 0.3% | -9.0 pts | SEC Filing (0001628280-23-001516) ↗ |
| FY2021 | Dec 31, 2021 | 9.3% | +23.9 pts | SEC Filing (0001104659-22-007648) ↗ |
| FY2020 | Dec 31, 2020 | -14.6% | -10.4 pts | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | -4.2% | -12.5 pts | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 8.3% | – | SEC Filing (0001104659-19-002848) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) U.S. — Reported Sales Growth (%) (%), annual FY2018–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-nm-yoy-rep-us
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.